

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of the claims in the application:

Listing of the claims:

1. (Currently Amended) A process for separating fibronectin from a plasma fraction comprising the steps of:
 - (i) adjusting the pH value of the plasma fraction, wherein said plasma fraction contains an initial amount of fibronectin and at least one coagulation factor and is characterized by an ionic strength below 500 mM, to below pH 5.4 a value between pH 4.7 and pH 5.3 so as to form a precipitate comprising 70% to 99% of the initial amount of fibronectin and a supernatant containing said at least one coagulation factor, the ionic strength of the plasma fraction being below 500 mM;
 - (ii) separating the fibronectin precipitate formed from the coagulation factor supernatant.
2. (Currently Amended) A process for the production of a composition containing at least one coagulation factor, comprising the steps of:
 - (i) adjusting the pH of a plasma fraction, wherein said plasma fraction contains an initial amount of fibronectin and at least one coagulation factor and is characterized by an ionic strength below 500 mM, to below pH 5.4 a value between pH 4.7 and pH 5.3 so as to form a precipitate comprising 70% to 99% of the initial amount of fibronectin and a supernatant containing said at least one coagulation factor, the ionic strength of the plasma fraction being below 500 mM; and
 - (ii) separating removing the fibronectin precipitate formed to thereby yield a composition containing at least one coagulation factor.

3. (Canceled) ~~The process according to claim 1, characterized in that the pH of the plasma fraction is adjusted to a value between pH 4.7 and pH 5.3.~~
4. (Previously Presented) The process according to claim 1, characterized in that the ionic strength of the plasma fraction is below 300 mM.
5. (Previously Presented) The process according claim 1, characterized in that the ionic strength of the plasma fraction is below 200 mM.
6. (Previously Presented) The process according to claim 1, characterized in that after adjusting the pH value in step (i), the plasma fraction is stirred for at least 10 minutes.
7. (Previously Presented) The process according to claim 1, characterized in that the majority of the fibronectin precipitate is separated by means of an agitator blade of a stirrer.
8. (Previously Presented) The process according to claim 1, characterized in that before step (i), the fibronectin concentration in the plasma fraction is at least 0.1 g per liter.
9. (Currently Amended) The process according to claim 1, characterized in that the ~~plasma fraction initially contains concentration of~~ NaCl or KCl ~~in the plasma fraction at a concentration of~~ 100 – 200 mM.
10. (Previously Presented) The process according to claim 1, characterized in that the plasma fraction initially contains glycine at a concentration below 500 mM.
11. (Previously Presented) The process according to claim 1, characterized in that the plasma fraction initially contains glycine at a concentration below 200 mM.

12. (Previously Presented) The process according to claim 1, characterized in that the plasma fraction initially contains glycine at a concentration of 50 to 200 mM.

13. (Currently Amended) The process according to claim 1, characterized in that the plasma fraction initially contains glycine at a concentration of 100 to 150 mM.

14. (Previously Presented) The process according to claim 1, characterized in that the plasma fraction is dissolved cryoprecipitate.

15. (Currently Amended) The process according to claim 14, characterized in that the dissolved cryoprecipitate is previously purified by ~~(a) treatment with~~ aluminum hydroxide treatment, ~~(b) treatment with a solvent and/or a detergent, treatment and~~ (c) anion exchange chromatography.

16. (Currently Amended) The process according to claim 1, characterized in that ~~the composition obtained in after step (ii) is further treated to yield~~ at least one purified coagulation factor ~~is purified~~.

17. (Original) The process according to claim 16, characterized in that the ~~at least one~~ coagulation factor is von Willebrand factor.

18. (Previously Presented) A coagulation factor obtained by a process according to claim 16.

19. (New) The process according to claim 1, wherein steps (i) and (ii) are performed at a temperature that ranges from 4° C. to 35° C.

20. (New) The process according to claim 1, wherein steps (i) and (ii) are performed at a temperature that ranges from 4° C. to 35° C.

21. (New) The process according to claim 1, wherein steps (i) and (ii) are performed at a temperature that ranges from 20° C to 25° C.

22. (New) The process according to claim 2, wherein steps (i) and (ii) are performed at a temperature that ranges from 20° C to 25° C.

23. (New) The process according to claim 1, wherein the fibronectin precipitate obtained in step (i) contains at least 90% of the initial amount of fibronectin.

24. (New) The process according to claim 2, wherein the fibronectin precipitate obtained in step (i) contains at least 90% of the initial amount of fibronectin.